Overview

Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A single dose of the study drug will be administered to healthy female subjects in a single period to obtain pharmacokinetic parameters for each active ingredient.
Phase:
Phase 1
Details
Lead Sponsor:
Exeltis Turkey
Collaborator:
Monitor CRO